Literature DB >> 8170938

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Y Kawakami1, S Eliyahu, C H Delgado, P F Robbins, L Rivoltini, S L Topalian, T Miki, S A Rosenberg.   

Abstract

By cDNA expression cloning we have isolated a gene encoding a shared human melanoma antigen recognized by HLA-A2 restricted autologous and allogenic tumor-infiltrating lymphocytes (TILs) from patients with metastatic melanoma. By using both transient and stable expression systems, transfection of this gene into non-antigen-expressing HLA-A2+ cell lines resulted in recognition by the antigen-specific TILs. The sequence of this cDNA revealed a previously undescribed putative transmembrane protein whose expression was restricted to melanoma and melanocyte cell lines and human retina but no other fresh or cultured normal tissues tested or other tumor histologies. Thus, we have identified a gene encoding a melanocyte lineage-specific protein (MART-1; melanoma antigen recognized by T cells 1) that is a widely shared melanoma antigen recognized by the T lymphocytes of patients with established malignancy. Identification of this gene opens possibilities for the development of immunotherapies for patients with melanoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8170938      PMCID: PMC43610          DOI: 10.1073/pnas.91.9.3515

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Authors:  A Knuth; T Wölfel; E Klehmann; T Boon; K H Meyer zum Büschenfelde
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

Authors:  T L Darrow; C L Slingluff; H F Seigler
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

3.  Vitiligo in patients with metastatic melanoma: a good prognostic sign.

Authors:  J J Nordlund; J M Kirkwood; B M Forget; G Milton; D M Albert; A B Lerner
Journal:  J Am Acad Dermatol       Date:  1983-11       Impact factor: 11.527

4.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

Authors:  L M Muul; P J Spiess; E P Director; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

5.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

6.  Prognostic significance of hypopigmentation in malignant melanoma.

Authors:  J C Bystryn; D Rigel; R J Friedman; A Kopf
Journal:  Arch Dermatol       Date:  1987-08

Review 7.  T-cell recognition of human melanoma antigens.

Authors:  Y Kawakami; M I Nishimura; N P Restifo; S L Topalian; B H O'Neil; J Shilyansky; J R Yannelli; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-08

8.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

9.  Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.

Authors:  B Seed; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

10.  Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.

Authors:  Y Kawakami; S A Rosenberg; M T Lotze
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

View more
  259 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Generation of MHC class I-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis.

Authors:  Y Yonamine; M Watanabe; F Kinjo; T Hibi
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

3.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma.

Authors:  M A Frassanito; A Cusmai; F Dammacco
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 4.  Hierarchy, tolerance, and dominance in the antitumor T-cell response.

Authors:  N P Restifo
Journal:  J Immunother       Date:  2001 May-Jun       Impact factor: 4.456

5.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

6.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

7.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

8.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

Review 9.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.

Authors:  Minoru Kitago; Kazuo Koyanagi; Takeshi Nakamura; Yasufumi Goto; Mark Faries; Steven J O'Day; Donald L Morton; Soldano Ferrone; Dave S B Hoon
Journal:  Clin Chem       Date:  2009-02-20       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.